Research Analysts Set Expectations for FENC Q2 Earnings

Fennec Pharmaceuticals Inc (NASDAQ:FENC - Free Report) - Investment analysts at HC Wainwright increased their Q2 2025 earnings estimates for shares of Fennec Pharmaceuticals in a research note issued to investors on Tuesday, May 20th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.07) for the quarter, up from their previous forecast of ($0.10). HC Wainwright currently has a "Buy" rating and a $13.00 target price on the stock. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is ($0.11) per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals' Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.14) EPS, Q1 2026 earnings at $0.06 EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.19 EPS and Q4 2026 earnings at $0.26 EPS.

Other research analysts have also issued reports about the stock. Craig Hallum upped their target price on shares of Fennec Pharmaceuticals from $12.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday, May 14th. Wedbush reaffirmed an "outperform" rating and set a $13.00 price objective on shares of Fennec Pharmaceuticals in a research note on Monday, March 10th.

Fennec Pharmaceuticals Trading Up 2.7%

Shares of FENC traded up $0.21 during mid-day trading on Thursday, reaching $8.08. 95,113 shares of the stock traded hands, compared to its average volume of 96,837. Fennec Pharmaceuticals has a 1 year low of $3.96 and a 1 year high of $8.56. The firm has a fifty day moving average price of $6.09 and a 200 day moving average price of $6.09. The company has a market cap of $223.27 million, a price-to-earnings ratio of -80.84 and a beta of 0.32.

Fennec Pharmaceuticals (NASDAQ:FENC - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.08. Fennec Pharmaceuticals had a negative net margin of 2.30% and a negative return on equity of 53.38%. The business had revenue of $8.51 million during the quarter, compared to analyst estimates of $8.18 million. During the same period in the previous year, the business earned $0.41 EPS.

Insider Buying and Selling at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Director Rosty Raykov sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, April 4th. The shares were sold at an average price of $5.25, for a total transaction of $52,500.00. Following the completion of the transaction, the director now owns 61,156 shares of the company's stock, valued at approximately $321,069. This trade represents a 14.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jeffrey S. Hackman purchased 13,965 shares of the business's stock in a transaction dated Monday, May 19th. The shares were purchased at an average price of $6.99 per share, for a total transaction of $97,615.35. Following the acquisition, the chief executive officer now owns 15,000 shares of the company's stock, valued at approximately $104,850. The trade was a 1,349.28% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 30,000 shares of company stock valued at $183,500. Corporate insiders own 11.76% of the company's stock.

Institutional Investors Weigh In On Fennec Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Solas Capital Management LLC grew its holdings in shares of Fennec Pharmaceuticals by 17.0% during the fourth quarter. Solas Capital Management LLC now owns 2,250,919 shares of the company's stock valued at $14,226,000 after buying an additional 327,383 shares during the last quarter. Rosalind Advisors Inc. purchased a new stake in shares of Fennec Pharmaceuticals during the fourth quarter valued at approximately $7,962,000. AIGH Capital Management LLC purchased a new stake in shares of Fennec Pharmaceuticals during the first quarter valued at approximately $2,199,000. Geode Capital Management LLC boosted its holdings in Fennec Pharmaceuticals by 1.3% in the fourth quarter. Geode Capital Management LLC now owns 303,090 shares of the company's stock worth $1,916,000 after purchasing an additional 3,792 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Fennec Pharmaceuticals by 10.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 61,146 shares of the company's stock worth $386,000 after purchasing an additional 5,694 shares during the last quarter. Hedge funds and other institutional investors own 55.51% of the company's stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.